The stock of XORTX Therapeutics Inc (NASDAQ: XRTX) has increased by 1.60 when compared to last closing price of 1.25. Despite this, the company has experienced a -3.05% fall in its stock price over the last five trading sessions. globenewswire.com reported 2024-12-12 that CALGARY, Alberta, Dec. 12, 2024 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce a presentation by Dr. Allen Davidoff at the Rare and Genetic Kidney Disease Summit, in Boston, Massachusetts at 10:30 am ET, Thursday December 12, 2024. The presentation entitled “Autosomal Dominant Polycystic Kidney Disease – Genetic and Environmental Factors → Evidence for Aberrant Purine Metabolism as a Second Hit Determining Disease Progression.”
Is It Worth Investing in XORTX Therapeutics Inc (NASDAQ: XRTX) Right Now?
The 36-month beta value for XRTX is also noteworthy at 0.50. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for XRTX is 3.37M, and at present, short sellers hold a 0.07% of that float. The average trading volume of XRTX on January 15, 2025 was 56.80K shares.
XRTX’s Market Performance
XRTX stock saw an increase of -3.05% in the past week, with a monthly gain of 4.96% and a quarterly increase of -16.99%. The volatility ratio for the week is 18.14%, and the volatility levels for the last 30 days are 12.56% for XORTX Therapeutics Inc (XRTX). The simple moving average for the past 20 days is 7.26% for XRTX’s stock, with a -33.19% simple moving average for the past 200 days.
XRTX Trading at 1.90% from the 50-Day Moving Average
After a stumble in the market that brought XRTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -81.86% of loss for the given period.
Volatility was left at 12.56%, however, over the last 30 days, the volatility rate increased by 18.14%, as shares surge +9.48% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -14.19% lower at present.
During the last 5 trading sessions, XRTX fell by -3.05%, which changed the moving average for the period of 200-days by -64.72% in comparison to the 20-day moving average, which settled at $1.1840. In addition, XORTX Therapeutics Inc saw 12.43% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for XRTX
The total capital return value is set at -3.22. Equity return is now at value -17.92, with -14.04 for asset returns.
Based on XORTX Therapeutics Inc (XRTX), the company’s capital structure generated 0.03 points at debt to capital in total, while cash flow to debt ratio is standing at -66.54.
Currently, EBITDA for the company is -4.87 million with net debt to EBITDA at 0.56. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.40.
Conclusion
In summary, XORTX Therapeutics Inc (XRTX) has had a mixed performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
